Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquinone biosynthesis protein COQ9, mitochondrial (COQ9) is a lipid-binding mitochondrial protein essential for the biosynthesis of coenzyme Q (ubiquinone), an important electron transporter in the mitochondrial respiratory chain required for aerobic cellular respiration. COQ9 directly interacts with COQ7 to facilitate an enzymatic hydroxylase step in coenzyme Q biosynthesis. Mutations in the COQ9 gene result in autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency, a rare mitochondrial disorder characterized by metabolic acidosis, encephalopathy, and multisystem organ involvement. COQ9 is therefore categorized as a potential therapeutic target, particularly in the context of rare mitochondrial disease.
Not applicable for direct drugs; coenzyme Q10 supplementation is hypothesized to remediate deficiency by bypassing biosynthetic defects
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquinone biosynthesis protein COQ9, mitochondrial (COQ9).